Back to news

INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis

PR Newswire•18/11/2026•08:05 ET
0

Key Highlights

  • ➤INOVIO submits EMA conditional marketing authorization application for VOCERYQ in adult RRP
  • ➤VOCERYQ received FDA accelerated approval October 30, 2026, reducing surgery frequency
  • ➤U.S. orders and shipments expected approximately 60 days after FDA approval
  • ➤Full U.S. commercial launch expected in first quarter of 2027
  • ➤European Commission granted VOCERYQ orphan drug designation in 2023

Expert Statements

Michael Sumner, Chief Medical Officer of INOVIO

“Building on the recent FDA approval of VOCERYQ, we believe there's significant opportunity to transform the treatment paradigm for RRP in Europe, a region that currently has no approved non-surgical treatment options that target the root cause of RRP.”

Michael Sumner, Chief Medical Officer of INOVIO

“We look forward to working closely with the EMA during the review and hope to ultimately provide RRP patients with a much-needed new treatment option that reduces the need for surgery.”

Frederik Dikkers, Professor emeritus of Otorhinolaryngology / Head and Neck Surgery at Amsterdam University Medical Center (Amsterdam UMC)

“Clinicians and patients alike understand that every surgery matters, because every surgery puts a patient's vocal cords at risk.”

Frederik Dikkers, Professor emeritus of Otorhinolaryngology / Head and Neck Surgery at Amsterdam University Medical Center (Amsterdam UMC)

“RRP affects patients around the world, and this submission is a meaningful step forward for those in Europe who have waited far too long for relief from this debilitating disease.”

INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis PR Newswire

* VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026 * Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe PLYMOUTH MEETING, Pa., Nov. 18, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in